This latest initiative from Pfizer’s Patient Affairs Liaisons team makes me think about collaborations and what that means for people with rare pituitary and endocrine diseases. The primary takeaway: when organizations work together, good things
Advocacy Zone
For patient support groups and advocates to share their stories, best practices, collaborate and get involved.
We want Congress to know more about Acromegaly: Join our effort!
An effort is under way to enable Acromegaly patients and doctors to make congress more aware of the needs of patients suffering from this disease. More details on this effort will be forthcoming soon. One
Making a difference
Today we begin a new series of feature articles that highlight the tireless work that people do to help others. Here are three amazing human beings: Jill Sisco runs the Acromegaly Community website and
Your gift changes lives!
We know that the increased awareness of pituitary disease is directly related to the higher probability of early diagnosis. Early diagnosis means quality of life, and in many cases increased life expectancy. Awareness is power
Diagnosing pituitary disease: patient views and perspectives
CLIK HERE TO DOWNLOAD THE “PATIENT VIEWS AND PERSPECTIVES” COMPILATION FROM PITUITARY WORLD NEWS. From Jorge D Faccinetti – co-founder Pituitary World News – Rare diseases, particularly those that come from the pituitary, are
A discussion about purpose
In October 2014 Dr. Lewis Blevins, Medical Director of the California Center for Pituitary Disorders and Professor of Clinical Medicine and Clinical Neurological Surgery at the University of California San Francisco, and I founded Pituitary World
Think different
First, I know “think different” is bad grammar as it should be “think differently”, but it really says it, doesn’t it? A few years ago, 1998 to be exact, Apple, Inc., (the then computer company)
One in Five …One in Eight. Who cares! One person not diagnosed is one too many.
From J D Faccinetti – There are several expert sources that have focused research on the prevalence of pituitary tumors. Estimates on these studies varied from as high as 30 percent to as low